EXLCUSIVE: Orgenesis Tells Benzinga 'Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027'
Portfolio Pulse from Benzinga Newsdesk
Orgenesis Inc. has agreed to give Metalmark a 5% royalty on the net revenue of Octomera's cell processing services for the years 2025-2027.
January 31, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Orgenesis Inc. will pay a 5% royalty to Metalmark on Octomera's cell processing services net revenue for three years, starting from 2025.
The agreement with Metalmark involves future revenues and is spread over three years, which may not have an immediate impact on ORGS's stock price. However, the commitment to pay royalties could indicate confidence in Octomera's revenue potential and the value of its cell processing services. The importance is moderate as it pertains to future revenue sharing and not current earnings.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100